Sphingosine-1-phosphate signaling and the skin

American Journal of Clinical Dermatology

Volumn 8, Issue 6, 2007, Pages 329-336

  Herzinger, Thomas ^a   Kleuser, Burkhard ^b   Schäfer Korting, Monika ^b   Korting, Hans Christian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Research and development; Sphingosine 1 phosphate, general

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AZATHIOPRINE; CYCLOSPORIN A; FINGOLIMOD; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SEW 2871; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONNECTIVE TISSUE; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN ALLOGRAFT; SURVIVAL TIME; T LYMPHOCYTE; VASCULAR SMOOTH MUSCLE;

EID: 36448996134     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708060-00002     Document Type: Review

References (106)

1. Schwab SR, Pereira JP, Matloubian M, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005; 309: 1735-9
2. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 1993; 365: 557-60
3. Edsall LC, Pirianov GG, Spiegel S. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J Neurosci 1997; 17: 6952-60
4. Mazurek N, Megidish T, Hakomori S, et al. Regulatory effect of phorbol esters on sphingosine kinase in BALB/C 3T3 fibroblasts (variant A31): demonstration of cell type-specific response: a preliminary note. Biochem Biophys Res Commun 1994; 198: 1-9
5. Kleuser B, Cuvillier O, Spiegel S. 1alpha,25-dihydroxyvitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. Cancer Res 1998; 58: 1817-24
6. Alemany R, Meyer zu Heringdorf D, van Koppen CJ, et al. Formyl peptide receptor signaling in HL-60 cells through sphingosine kinase. J Biol Chem 1999; 274: 3994-9
7. Melendez A, Floto RA, Cameron AJ, et al. A molecular switch changes the signalling pathway used by the Fc gamma RI antibody receptor to mobilise calcium. Curr Biol 1998; 8: 210-21
8. Zhang H, Desai NN, Olivera A, et al. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 1991; 114: 155-67
9. Lee MJ, Van Brocklyn JR, Thangada S, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998; 279: 1552-5
10. Pyne S. Cellular signaling by sphingosine and sphingosine 1-phosphate: their opposing roles in apoptosis. Subcell Biochem 2002; 36: 245-68
11. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 2003; 47: 401-7
12. Waeber C, Blondeau N, Salomone S. Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. Drug News Perspect 2004; 17: 365-82
13. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-60
14. Graler MH, Bernhardt G, Lipp M. A lymphoid tissue-specific receptor, EDG6, with potential immune modulatory functions mediated by extracellular lysophospholipids. Curr Top Microbiol Immunol 1999; 246: 131-6
15. Terai K, Soga T, Takahashi M, et al. Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience 2003; 116: 1053-62
16. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. Biochim Biophys Acta 2002; 1582: 112-20
17. Taha TA, Argraves KM, Obeid LM. Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. Biochim Biophys Acta 2004; 1682: 48-55
18. Davaille J, Gallois C, Habib A, et al. Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts: a cyclooxygenase-2 mediated pathway. J Biol Chem 2000; 275: 34628-33
19. Morales-Ruiz M, Lee MJ, Zollner S, et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem 2001; 276: 19672-7
20. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99: 301-12
21. Paik JH, Chae S, Lee MJ, et al. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem 2001; 276: 11830-7
22. Lee H, Goetzl EJ, An S. Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am J Physiol Cell Physiol 2000; 278: C612-8
23. Igarashi J, Bernier SG, Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase: differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem 2001; 276: 12420-6
24. di Villa Bianca R, Sorrentino R, Imbimbo C, et al. Sphingosine 1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum. J Pharmacol Exp Ther 2006; 316: 703-8
25. Coussin F, Scott RH, Wise A, et al. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 2002; 91: 151-7
26. Ohmori T, Yatomi Y, Osada M, et al. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res 2003; 58: 170-7
27. Tosaka M, Okajima F, Hashiba Y, et al. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke 2001; 32: 2913-9
28. Liu Y, Wada R, Yamashita T, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000; 106: 951-61
29. Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 2003; 102: 3665-7
30. Kono M, Mi Y, Liu Y, et al. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 2004; 279: 29367-73
31. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66: 221-31
32. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278: 47281-90
33. Schaphorst KL, Chiang E, Jacobs KN, et al. Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol 2003; 285: L258-67
34. Dudek SM, Jacobson JR, Chiang ET, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem 2004; 279: 24692-700
35. McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem 2004; 92: 1075-85
36. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280: 17286-93
37. Jin ZQ, Zhou HZ, Zhu P, et al. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002; 282: H1970-7
38. Graler MH, Goetzl EJ. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim Biophys Acta 2002; 1582: 168-74
39. Allende ML, Dreier JL, Mandala S, et al. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 2004; 279: 15396-401
40. Graler MH, Huang MC, Watson S, et al. Immunological effects of transgenic constitutive expression of the type 1 sphingosine 1-phosphate receptor by mouse lymphocytes. J Immunol 2005; 174: 1997-2003
41. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-7
42. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-9
43. Albert R, Hinterding K, Brinkmann V, et al. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 2005; 48: 5373-7
44. Kharel Y, Lee S, Snyder AH, et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 2005; 280: 36865-72
45. Allende ML, Sasaki T, Kawai H, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 2004; 279: 52487-92
46. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 5761-70
47. Brinkmann V, Chen S, Feng L, et al. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 2001; 33: 530-1
48. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. Faseb J 2004; 18: 551-3
49. Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005; 6: 1228-35
50. Renkl A, Berod L, Mockenhaupt M, et al. Distinct effects of sphingosine-1-phosphate, lysophosphatidic acid and histamine in human and mouse dendritic cells. Int J Mol Med 2004; 13: 203-9
51. Czeloth N, Bernhardt G, Hofmann F, et al. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J Immunol 2005; 175: 2960-7
52. Eigenbrod S, Derwand R, Jakl V, et al. Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells. Immunol Invest 2006; 35: 149-65
53. Melendez AJ, Khaw AK. Dichotomy of Ca2+ signals triggered by different phospholipid pathways in antigen stimulation of human mast cells. J Biol Chem 2002; 277: 17255-62
54. Choi OH, Kim JH, Kinet JP. Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor. Nature 1996; 380: 634-6
55. Jolly PS, Bektas M, Olivera A, et al. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 2004; 199: 959-70
56. Olivera A, Rivera J. Sphingolipids and the balancing of immune cell function: lessons from the mast cell. J Immunol 2005; 174: 1153-8
57. Roviezzo F, Del Galdo F, Abbate G, et al. Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. Proc Natl Acad Sci U S A 2004; 101: 11170-5
58. Sawicka E, Zuany-Amorim C, Manlius C, et al. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol 2003; 171: 6206-14
59. Yanagawa Y, Hoshino Y, Chiba K. The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival. Int J Immunopharmacol 2000; 22: 597-602
60. Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms: I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 1996; 28: 1056-9
61. Nikolova Z, Hof A, Baumlin Y, et al. Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to Lewis heart and skin transplantation models. Transpl Immunol 2001; 8: 267-77
62. Lima RS, Nogueira-Martins MF, Silva Jr HT, et al. FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination. Transplant Proc 2004; 36: 1015-7
63. Chiba K, Hoshino Y, Ohtsuki M, et al. Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: I. Prevention of allograft rejection in rats and dogs by FTY720 and FTY720-phosphate. Transplant Proc 2005; 37: 102-6
64. Kohno T, Tsuji T, Hirayama K, et al. A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice. Biol Pharm Bull 2004; 27: 1392-6
65. Alperovich G, Rama I, Lloberas N, et al. New immunosuppressor strategies in the treatment of murine lupus nephritis. Lupus 2007; 16: 18-24
66. Okazaki H, Hirata D, Kamimura T, et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 2002; 29: 707-16
67. Castillo SS, Teegarden D. Sphingosine-1-phosphate inhibition of apoptosis requires mitogen-activated protein kinase phosphatase-1 in mouse fibroblast C3H10T 1/2 cells. J Nutr 2003; 133: 3343-9
68. Kiss Z, Mukherjee JJ. Phosphocholine and sphingosine-1-phosphate synergistical-ly stimulate DNA synthesis by a MAP kinase-dependent mechanism. FEBS Lett 1997; 412: 197-200
69. Olivera A, Kohama T, Edsall L, et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 1999; 147: 545-58
70. Zhang Q, Peyruchaud O, French KJ, et al. Sphingosine 1-phosphate stimulates fibronectin matrix assembly through a Rho-dependent signal pathway. Blood 1999; 93: 2984-90
71. Sato M, Markiewicz M, Yamanaka M, et al. Modulation of transforming growth factor-beta (TGF-beta) signaling by endogenous sphingolipid mediators. J Biol Chem 2003; 278: 9276-82
72. Yamanaka M, Shegogue D, Pei H, et al. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. J Biol Chem 2004; 279: 53994-4001
73. Xin C, Ren S, Eberhardt W, et al. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol 2006; 147: 164-74
74. Hamanaka S, Hara M, Nishio H, et al. Human epidermal glucosylceramides are major precursors of stratum corneum ceramides. J Invest Dermatol 2002; 119: 416-23
75. Behne M, Uchida Y, Seki T, et al. Omega-hydroxyceramides are required for corneocyte lipid envelope (CLE) formation and normal epidermal permeability barrier function. J Invest Dermatol 2000; 114: 185-92
76. Bektas M, Orfanos CE, Geilen CC. Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol Biol 2000; 46: 111-9
77. Vogler R, Sauer B, Kim DS, et al. Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. J Invest Dermatol 2003; 120: 693-700
78. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990; 63: 245-7
79. Sauer B, Vogler R, von Wenckstern H, et al. Involvement of Smad signaling in sphingosine 1-phosphate-mediated biological responses of keratinocytes. J Biol Chem 2004; 279: 38471-9
80. Manggau M, Kim DS, Ruwisch L, et al. 1alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 2001; 117: 1241-9
81. Kim DS, Kim SY, Kleuser B, et al. Sphingosine-1-phosphate inhibits human keratinocyte proliferation via Akt/protein kinase B inactivation. Cell Signal 2004; 16: 89-95
82. Marcinkowska E, Wiedlocha A, Radzikowski C. 1,25-dihydroxyvitamin D3 induced activation and subsequent nuclear translocation of MAPK is upstream regulated by PKC in HL-60 cells. Biochem Biophys Res Commun 1997; 241: 419-26
83. Xia P, Gamble JR, Wang L, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000; 10: 1527-30
84. Kawamori T, Osta W, Johnson KR, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. Faseb J 2006; 20: 386-8
85. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63: 5962-9
86. Van Brocklyn JR, Jackson CA, Pearl DK, et al. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005; 64: 695-705
87. Yamaguchi H, Kitayama J, Takuwa N, et al. Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem J 2003; 374: 715-22
88. Arikawa K, Takuwa N, Yamaguchi H, et al. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor: requirement of inhibition of cellular RAC activity. J Biol Chem 2003; 278: 32841-51
89. Birt DF, Merrill Jr AH, Barnett T, et al. Inhibition of skin carcinomas but not papillomas by sphingosine, N-methylsphingosine, and N-acetylsphingosine. Nutr Cancer 1998; 31: 119-26
90. Visentin B, Vekich JA, Sibbald BJ, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006; 9: 225-38
91. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-4
92. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35
93. Tanaka T, Takahara S, Hatori M, et al. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett 2002; 181: 165-71
94. Schmid G, Guba M, Ischenko I, et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem 2007; 101: 259-70
95. Bibel DJ, Aly R, Shinefield HR. Antimicrobial activity of sphingosines. J Invest Dermatol 1992; 98: 269-73
96. Bibel DJ, Miller SJ, Brown BE, et al. Antimicrobial activity of stratum corneum lipids from normal and essential fatty acid-deficient mice. J Invest Dermatol 1989; 92: 632-8
97. Bibel DJ, Aly R, Shah S, et al. Sphingosines: antimicrobial barriers of the skin. Acta Derm Venereol 1993; 73: 407-11
98. Bibel DJ, Aly R, Shinefield HR. Topical sphingolipids in antisepsis and antifungal therapy. Clin Exp Dermatol 1995; 20: 395-400
99. Pavicic T, Wollenwebert U, Farwickt M, et al. Antimicrobial and anti-inflammatory activity and efficacy of phytosphingosine: an in-vitro and in-vivo study addressing acne vulgaris. Int J Cosmet Sci 2007; 29: 181-90
100. Kim S, Hong I, Hwang JS, et al. Phytosphingosine stimulates the differentiation of human keratinocytes and inhibits TPA-induced inflammatory epidermal hyperplasia in hairless mouse skin. Mol Med 2006; 12: 17-24
101. Forrest M, Sun SY, Hajdu R, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004; 309: 758-68
102. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279: 13839-48
103. Li Z, Chen W, Hale JJ, et al. Discovery of potent 3,5-diphenyl-1,2,4- oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivi-ty against S1P2 and S1P3. J Med Chem 2005; 48: 6169-73
104. Garg SK, Volpe E, Palmieri G, et al. Sphingosine 1-phosphate induces antimicrobial activity both in vitro and in vivo. J Infect Dis 2004; 189: 2129-38
105. Davis MD, Clemens JJ, Macdonald TL, et al. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 2005; 280: 9833-41
106. Szentpetery V. Partikel gegen Pickel. Technol Rev 2006; 11: 10